Dr. Rachel Tate uptoTate
6 years 4 months ago
#EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassurance to rheums and pts regarding immunosuppression and COVID19. The compiled data from over 600 pts in 40 countries. @RheumNow
https://t.co/qMwGJTL041
Dr. Rachel Tate uptoTate
6 years 4 months ago
Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate
6 years 4 months ago
Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
Dr. Rachel Tate uptoTate
6 years 4 months ago
Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc
Dr. Rachel Tate uptoTate
6 years 4 months ago
This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4
Dr. Rachel Tate uptoTate
6 years 4 months ago
Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULAR2020 @RheumNow https://t.co/Zb2RrqSIaK https://t.co/2z1HMQ3b5G
Dr. Rachel Tate uptoTate
6 years 4 months ago
This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T
Dr. Rachel Tate uptoTate
6 years 4 months ago
Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow
Dr. John Cush RheumNow
6 years 4 months ago
CEE= Central Easter Europe compared to US https://t.co/Zw4HPnZ8Id
Dr. Rachel Tate uptoTate
6 years 4 months ago
nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5
Dr. Rachel Tate uptoTate
6 years 4 months ago
COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396
https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K
Dr. Rachel Tate uptoTate
6 years 4 months ago
SEC shows improvement in both tender and swollen peripheral joints in AS pts. #EULAR2020 @RheumNow poster #THU0397
https://t.co/M0D6Ruh8ta https://t.co/kuShSUhXbf
Dr. Rachel Tate uptoTate
6 years 4 months ago
Thoughts on the #EULAR2020 e-congress? As a life long learner, I’ve enjoyed being able to attend but I miss my interactions with colleagues @RheumNow
Dr. Rachel Tate uptoTate
6 years 4 months ago
Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw
Dr. Rachel Tate uptoTate
6 years 4 months ago
This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A

